Active options: CSCO TEVA ABX WM FB TEVA NFLX
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
The Oracle of Omaha Goes Value Shopping in the Value Pharmaceutical Bin with Teva (TEVA)
February 15, 2018 12:26 PM ESTWith countless missteps, U.S. generics business weakness, Copaxone generic competition, and an ongoing restructuring, Teva Pharma (NYSE: TEVA) has been labeled your classic "dog" stock for the past couple of years. That all changed yesterday when Warren Buffett's Berkshire Hathaway shocked Wall Street by disclosing in their December-quarter 13F that they had accumulated a new, nearly 19 million share position in the Isreal-based pharmaceutical company.
While it is unclear if the Oracle himself pulled the trigger on the trade, all of Berkshire's lieutenants try to stick to... More
